1 table omitted
Persons with diabetes are more likely to be visually impaired than persons without the disease.1 In 2005, CDC estimated that 14.6 million persons in the United States had diagnosed diabetes and an additional 6.2 million had undiagnosed diabetes.2 Despite the importance of detecting and treating vision problems caused by refractive errors (i.e., correctable visual impairment [CVI]), a limited number of studies have attempted to determine the proportion of persons with diabetes whose poor vision could be corrected with accurately prescribed glasses or contact lenses. To estimate that proportion, CDC analyzed 1999-2004 data from the National Health and Nutrition Examination Survey (NHANES). This report describes the results of that analysis, which indicated that among U.S. adults aged ≥20 years with diabetes,* 11.0% had visual impairment (i.e., presenting visual acuity worse than 20/40 in their better-seeing eye while wearing glasses or contact lenses, if applicable) and approximately 65.5% of these cases of visual impairment were correctable. Health-care providers and persons with diabetes should be more aware that poor vision often is correctable and that visual corrections can reduce the risk for injury and improve the quality of life for persons with diabetes.
NHANES is an ongoing series of cross-sectional surveys on health and nutrition designed to be nationally representative of the noninstitutionalized, U.S. civilian population by using a complex, multistage probability design. All NHANES surveys include a household interview followed by a detailed physical examination. For the 1999-2000, 2001-2002, and 2003-2004 surveys, participants also were asked questions regarding vision function, and the physical examination included a vision examination in which visual acuity was measured before and after an objective autorefraction test (optical correction measured by an autorefractor). In this study, visual acuity before correction was defined as distance visual acuity with whatever form of current correction (e.g., glasses or contact lenses) the participant might have worn at the time of examination. Visual acuity after correction was defined as potential visual acuity as assessed by an objective autorefraction test. Only those participants whose visual acuity before correction was worse than 20/30 were administered the autorefraction test. Diabetes was defined as a self-reported previous diagnosis of the disease. In the NHANES surveys conducted during 1999-2004, the combined household interview response rate was approximately 82%, and the medical examination response rate was 77%. Of 15,332 adults aged ≥20 years, 22 were excluded because of lack of diabetes information or because their diabetes was diagnosed only during pregnancy. Another 2,306 adults for whom visual acuity before correction values were missing were excluded from the study.
For this analysis, 1,237 adults aged ≥20 years with self-reported diabetes were divided into three groups according to their visual acuity in the better-seeing eye (before and after optical correction): (1) normal: visual acuity of 20/40 or better; (2) mild impairment: visual acuity better than 20/200 and worse than 20/40; and (3) severe impairment: visual acuity of 20/200 or worse. The prevalence of CVI was defined as the proportion of adults with mild or severe impairment before correction who were found to have the potential for normal visual acuity after correction. All analyses were weighted to make estimates representative of the U.S. civilian, noninstitutionalized population. Results also were analyzed by age group (20-64 years compared with ≥65 years), sex, and race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, and other).
Overall, the prevalence of CVI among U.S. adults aged >20 years with diabetes was 7.2%, which indicated that the proper prescription for glasses or contact lenses would have restored normal visual acuity to 65.5% of visually impaired adults with diabetes. The results indicated that 9.7% (95% CI [confidence interval] = 7.9%-11.8%) of U.S. adults with diabetes had mild visual impairment, and 1.4% (CI = 1.0%-1.9%) had severe visual impairment before correction; 2.9% (CI = 2.1%-3.9%) had mild impairment, and 1.0% (CI = 0.6%-1.5%) had severe impairment after correction. Approximately 0.3% of adults with diabetes who had severe visual impairment before correction had only mild visual impairment after correction. Thus, optical correction would have restored normal visual acuity to approximately 73.4% of adults with mild impairment and 9.1% of adults with severe impairment.
Although the crude prevalence of CVI among adults aged ≥65 years with diabetes (7.3%) was similar to that among those aged 20-64 years (7.2%), 89.2% of visual impairment cases among the younger age group were correctable, compared with 46.4% of cases among the older age group. The age-adjusted prevalence of CVI was similar among men (7.3%) and women (7.2%). Although not statistically significant, the age-adjusted prevalence of CVI was higher among non-Hispanic blacks (7.9%) and Mexican Americans (8.1%) than among non-Hispanic whites (5.6%).
X Zhang, MD, PhD, EW Gregg, PhD, YJ Cheng, MD, PhD, T Thompson, MS, LS Geiss, MS, MR Duenas, OD, JB Saaddine, MD, MPH, Div of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, CDC.
This report describes the first nationally representative study to estimate the proportion of U.S. adults with diabetes who have visual impairment that can be corrected. The findings indicate that nearly two-thirds of adults with diabetes who have visual impairment can correct their vision with an accurate corrective prescription for glasses or contact lenses. This finding underscores the importance of public awareness and public health intervention in reducing the prevalence of CVI, especially among persons with diabetes. However, although simple eye examinations and the provision of prescription glasses or contact lenses can correct or improve most cases of visual impairment caused by refractive errors, persons with diabetes also can have ocular complications such as diabetic retinopathy, which is the leading cause of legal blindness in the United States. Persons with diabetes are recommended to have yearly dilated eye examinations or fundus photography to ensure early detection and timely treatment of the ocular complications of diabetes.
CVI has been documented in several population-based studies3- 6 and has been determined to be related to reduced quality of life and increased mortality.7- 9 One study reported that approximately 50% of participants had improved vision after refractive correction.6 Another study found that uncorrected refractive error accounted for nearly 73% of the cases of impaired visual acuity among Mexican Americans aged ≥40 years,5 and similar findings were reported among residents in the United Kingdom7 and Australia.10 Moreover, on the basis of NHANES data from 1999-2002, the National Eye Institute reported the first nationally representative estimates of the prevalence of CVI in the general population (5.3%) and emphasized the importance of correcting visual impairments caused by refractive error as a means of improving safety (e.g., by reducing the risk for unintentional injuries, particularly falls) and quality of life for those affected by such impairments.1
The findings in this report are subject to at least five limitations. First, because institutionalized persons (e.g., nursing home residents) are excluded from NHANES participation, the overall prevalence of visual impairment among U.S. adults with diabetes likely was underestimated. Second, the exclusion of potential study participants who were completely blind, were unable to see in both eyes, or had a severe infection in one or both eyes might have resulted in lower prevalence estimates of visual impairment. Third, because this study measured only objective refraction and performed no subjective refinement of objective refraction measurements, estimates of visual acuity after correction might not reflect the best corrected vision that participants might attain, resulting in an underestimate of CVI prevalence. Fourth, although visual acuity of survey participants was measured with whatever glasses or contact lenses they wore at the time of examination, certain participants might not have had their current corrective devices at that time, a factor that might have led to an overestimate of CVI prevalence. Finally, certain estimates had a relative standard error of >30% and thus are considered statistically unreliable.
CDC collaborates with the National Eye Institute through the National Eye Health Education Program to increase public and professional awareness of the importance of routine eye examinations. CDC also provides resources and technical assistance to states and nonprofit organizations (e.g., Prevent Blindness America) to help them increase their surveillance of vision loss and eye diseases, increase public awareness of how to prevent vision loss, and generally promote eye health to reduce the public burden of visual impairment.
The findings of this study underscore a continued need for national visual acuity data from representative U.S. population surveys. These data are essential to the planning, implementation, and evaluation of public health practices designed to reduce the burden of visual impairment among persons with diabetes in the United States.
The high prevalence of CVI among persons with diabetes indicates a need for enhanced vision-related public health interventions (e.g., vision screening) among adults with diabetes. The findings of this study also suggest that the use of visual acuity and refractive error assessments in concert with recommended dilated eye examinations might further contribute to improved vision outcomes for adults with diabetes. Identifying and pursuing ways of increasing access to eye care and ensuring that those with CVI receive appropriate vision correction will help reduce the morbidity and mortality among persons with diabetes associated with impaired vision and help persons achieve optimal vision and eye health.
This report is based, in part, on contributions by KM Venkat Narayan, MD, and J Wang, MD, Div of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, CDC.
*Excludes persons with diabetes who were completely blind, unable to see in both eyes, or with a severe infection in one or both eyes.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and
Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early
dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
Users' Guides to the Medical Literature
Example 1: Diabetes and Target Blood Pressure
Users' Guides to the Medical Literature
For example, researchers who conducted a randomized trial of a diabetes education program...
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.